JOURNAL OF ADDICTIONS & OFFENDER COUNSELING, published by Wiley, serves as a critical platform for interdisciplinary research at the intersection of psychology, law, and social issues related to addictions and criminal behavior. With a commitment to excellence since its inception in 1990, this journal boasts an impressive Scopus rank within the top quartiles of its fields—ranking Q2 in Law and Q3 in both Clinical and Social Psychology as of 2023. While currently not designated as an Open Access publication, it provides a wealth of peer-reviewed articles that promote the understanding and counseling of offenders, making it invaluable for researchers, practitioners, and students alike. The journal addresses critical contemporary issues, fostering discussions that influence policy and therapeutic practices, ensuring its vital role in advancing knowledge and effective interventions in addiction and offender counseling.

Substance Abuse and Rehabilitation, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the study and treatment of substance abuse and related rehabilitation practices. With its ISSN 1179-8467, this journal provides a vital platform for researchers, clinicians, and students to disseminate their findings and insights in a field increasingly relevant to public health. Since becoming open access in 2010, the journal has enhanced its reach, allowing for a broader audience to engage with cutting-edge research and reviews that address the complexities of substance abuse disorders. The journal aims to foster innovation and interdisciplinary collaboration by publishing high-quality peer-reviewed articles that cover a wide range of topics, including addiction therapy, policy implications, and the social determinants of substance use. As a vital resource within the realm of addiction research, Substance Abuse and Rehabilitation plays a crucial role in driving forward knowledge and practices that can improve outcomes for individuals and communities affected by substance use issues.

Journal of Substance Use & Addiction Treatment is a premier scholarly publication dedicated to advancing the understanding and treatment of substance use disorders and addictive behaviors. Published by Elsevier Science Inc, this journal serves as a vital platform for researchers, clinicians, and students in the fields of psychology, psychiatry, public health, and addiction studies. With its commitment to Open Access, the journal facilitates wide dissemination of cutting-edge research, enabling practitioners and policymakers to access critical findings that inform treatment approaches and public health strategies. As an essential resource in addiction treatment and research, the Journal of Substance Use & Addiction Treatment aims to foster interdisciplinary collaboration and innovation, ultimately improving outcomes for individuals affected by addiction.

Addiction Science & Clinical Practice is a premier open-access journal dedicated to advancing the understanding and treatment of addiction through evidence-based research and clinical practice. Published by BMC in the United Kingdom since 2007, this journal has significantly impacted the fields of Clinical Psychology, Medicine, and Psychiatry and Mental Health, proudly securing a Q1 ranking in multiple categories as of 2023. With an emphasis on high-quality research, the journal provides an inclusive platform for the dissemination of innovative findings and clinical insights that address the complexities of addiction. Researchers, practitioners, and students alike benefit from its unrestricted access since 2012, allowing for widespread dissemination of knowledge. Located at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to lead the way in fostering collaboration and informing best practices in addiction science.

Canadian Journal of Addiction is a leading platform dedicated to advancing the understanding of addiction and its multifaceted impacts on individuals and society. Published by LIPPINCOTT WILLIAMS & WILKINS, this journal aims to foster rigorous research and discussion in the field of addiction studies, contributing significantly to the intersection of psychiatry and mental health. With its ISSN 2368-4720 and E-ISSN 2368-4739, the journal is indexed in Scopus and has been categorized in the Q3 quartile for 2023, reflecting its emerging influence amongst peers. The Canadian Journal of Addiction facilitates a vital exchange of ideas and findings, crucial for researchers, practitioners, and students alike, addressing pressing issues related to addiction through innovative studies and insightful reviews. Subscribers and readers benefit from the latest findings as they navigate through the dynamic landscape of addiction research, enriching both academic knowledge and practical applications.

The Journal of Addictions Nursing, published by Lippincott Williams & Wilkins, serves as a pivotal resource in the field of psychiatric and mental health nursing. With an ISSN of 1088-4602 and an E-ISSN of 1548-7148, this esteemed journal has been dedicated to advancing the knowledge and practice of addiction nursing since its inception in 1989. As of 2023, it ranks in the Q3 category of psychiatry and mental health, highlighting its significance amidst its peers. The journal provides a platform for the dissemination of original research, reviews, and clinical practices that address the complexities of addiction treatment and care. While it currently does not offer open access options, its valuable insights are accessible to practitioners and researchers committed to improving patient outcomes. With content spanning from 1989 to 2024, the journal continues to shape the discourse in this vital area of nursing, making it an essential read for professionals and scholars aiming to stay at the forefront of addiction nursing and intervention strategies.

Substance Abuse is a premier scholarly journal published by SAGE Publications Inc, dedicated to advancing the understanding and treatment of substance use disorders. With an established presence from 1995 to 2023, the journal boasts an impressive Q1 ranking in both Medicine (miscellaneous) and Psychiatry and Mental Health, positioning it among the top tier of academic publications in these fields. Researchers and professionals will find its articles, which are grounded in rigorous empirical studies and innovative interventions, essential for addressing the complex and multifaceted nature of substance abuse. Although not an open access publication, Substance Abuse maintains a commitment to sharing valuable insights and findings, making it a vital resource for those looking to enhance their knowledge and practice. Located in Thousand Oaks, CA, this journal serves as a critical forum for international dialogue and research dissemination, ensuring that current trends and challenges in substance use are thoughtfully examined and discussed within the academic community.

The Journal of Substance Use is a vital resource for researchers, professionals, and students in the fields of health and social sciences, published by Taylor & Francis Inc.. With an ISSN of 1465-9891 and E-ISSN of 1475-9942, this journal has been at the forefront of substance use research since its inception in 1996 and continues to provide a platform for the dissemination of innovative findings and critical analysis up to the year 2024. Ranking in the Q3 category for both Health (Social Science) and Medicine (Miscellaneous) in the 2023 quartiles, the journal encapsulates a broad spectrum of issues related to substance use, including addiction, intervention strategies, and policy implications. Although not an open-access journal, it remains accessible to a wide audience. With its substantial role in enhancing understanding and addressing the multi-faceted challenges of substance use, the Journal of Substance Use is essential for all stakeholders aiming to contribute to research and practice in this crucial area.

The Journal of Dual Diagnosis, published by Routledge Journals, Taylor & Francis Ltd, is a leading interdisciplinary platform dedicated to the critical study of co-occurring mental health and substance use disorders. With its ISSN 1550-4263 and E-ISSN 1550-4271, this esteemed journal has been at the forefront of advancing research and clinical practice since its inception in 2004, and continues to serve as a vital resource until 2024. Ranked in the second quartile (Q2) in Psychiatry and Mental Health and positioned at the 64th percentile in the Scopus rankings, it emphasizes the importance of integrating care across various domains of health. Although not open access, it offers a wealth of peer-reviewed articles, case studies, and reviews suitable for researchers, practitioners, and students alike, aiming to enhance our understanding and treatment of dual diagnosis. The journal's commitment to addressing the complexities of dual disorders not only informs research but also shapes policy and clinical guidelines, making it an essential read for anyone involved in these critical areas of mental health.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, published by the American Psychological Association, stands as a pivotal resource within the fields of pharmacology and psychiatry. With an ISSN of 1064-1297 and an E-ISSN of 1936-2293, this journal contributes significantly to the understanding of psychopharmacological interventions through its rich array of research articles, reviews, and clinical studies. Classified within the Q2 category in both Pharmacology and Psychiatry and Mental Health, it reflects a solid standing in academic performance, evidenced by its rankings in Scopus, where it places within the top half of its categories. Spanning from 1993 to 2024, it seeks to provide an essential platform for the dissemination of knowledge and advancements that influence clinical practice and therapeutic approaches. Although not an open-access journal, its impact on the development of evidence-based psychopharmacological treatments cannot be overstated, making it a vital resource for researchers, clinically active professionals, and students eager to stay abreast of cutting-edge developments in mental health and pharmacology.